Supernus Pharmaceuticals Inc (FRA:S49)
€ 34.6 0.6 (1.76%) Market Cap: 1.97 Bil Enterprise Value: 1.62 Bil PE Ratio: 34.78 PB Ratio: 2.04 GF Score: 80/100

Supernus Pharmaceuticals Inc to Discuss the SPN-812 Phase III Topline Results - Conference Call Transcript

Mar 28, 2019 / 01:00PM GMT
Release Date Price: €30.38 (+0.10%)
Operator

Good morning, ladies and gentlemen, and welcome to the Supernus Pharmaceuticals conference call to discuss top line results of its Phase III study of SPN-812 in adolescents with attention deficit hyperactivity disorder. (Operator Instructions) As a reminder, this conference call is being recorded. I would now like to turn the conference over to Peter Vozzo of Westwicke Partners, Investor Relations for Supernus Pharmaceuticals. You may begin.

Peter Vozzo
Westwicke Partners, LLC - MD

Thank you, Shannon. Good morning, everyone, and thank you for joining us today for Supernus Pharmaceuticals conference call to discuss the top line results of its Phase III study of SPN-812 in adolescents with ADHD.

This morning, the company issued a press release announcing these top line results.

On the call with me today are Supernus' Chief Executive Officer, Jack Khattar; Chief Medical Officer, Stefan Schwabe; and Chief Financial Officer, Greg Patrick.

Today's call and associated slides are being made available via the Investor Relations section of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot